fluorobenzenes has been researched along with Arteriosclerosis in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 11 (73.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Sehara, Y; Tanahashi, N | 1 |
| Lin, ZP; Shu, PC; Wu, SQ; Zhang, RK; Zhang, ZW | 1 |
| McTaggart, F | 1 |
| Emeis, JJ; Fontijn, RD; Havekes, LM; Horrevoets, AJ; Jukema, JW; Kleemann, R; Kooistra, T; Princen, HM | 1 |
| Bernini, F; Catapano, AL | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Chapman, MJ; Copin, C; Davidson, R; Fruchart, JC; Furman, C; Kandoussi, M; McTaggiart, F; Moreau, M; Rouis, M | 1 |
| Bots, ML; Crouse, JR; Evans, GW; Grobbee, DE; O'Leary, DH; Palmer, MK; Raichlen, JS; Riley, WA | 1 |
| Chen, J; Li, D; Mehta, JL; Schaefer, RF | 1 |
| Dallongeville, J; Farnier, M; Ferrières, J; Lepen, C; Schuster, H | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Olsson, AG | 1 |
| Berliner, JA; Faull, KF; Fogelman, AM; Hörkkö, S; Leitinger, N; Navab, M; Palinski, W; Salomon, RG; Schwenke, D; Sha, W; Subbanagounder, G; Watson, AD; Witztum, JL | 1 |
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Adriaensen, H; Brugmans, J; De Cock, W; Dony, J; Jageneau, A; Roels, V; Schuermans, V; Verhaegen, H | 1 |
4 review(s) available for fluorobenzenes and Arteriosclerosis
| Article | Year |
|---|---|
Comparative pharmacology of rosuvastatin.
Topics: Arteriosclerosis; Cholesterol, LDL; Endothelium, Vascular; Fluorobenzenes; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
[Rosuvastatin: pharmacologic features].
Topics: Animals; Arteriosclerosis; Biotransformation; Cholesterol; Drug Interactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2003 |
[Hypercholesterolemia, practical guidelines].
Topics: Arteriosclerosis; C-Reactive Protein; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2004 |
Expanding options with a wider range of rosuvastatin doses.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Education, Continuing; Europe; Fluorobenzenes; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MEDLINE; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States | 2006 |
5 trial(s) available for fluorobenzenes and Arteriosclerosis
| Article | Year |
|---|---|
[Effects of rosuvastatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein in hypertensive patients with mild LDL-C elevation].
Topics: Aged; Arteriosclerosis; C-Reactive Protein; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ventricular Function, Left | 2010 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study.
Topics: Arteriosclerosis; C-Reactive Protein; Carotid Stenosis; Double-Blind Method; Drug Administration Schedule; Fluorobenzenes; Humans; Lipid Metabolism; Lipids; Multicenter Studies as Topic; Patient Selection; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tunica Intima; Tunica Media; Ultrasonography | 2004 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
The arteriolar effects of cinnarizine and flunarizine. Multitechnical investigations in normal volunteers and in patients with occlusive disease of the extremities secondary to arteriosclerosis.
Topics: Adult; Aged; Arteries; Arteriosclerosis; Blood Pressure; Cinnamates; Dose-Response Relationship, Drug; Evaluation Studies as Topic; Female; Fluorobenzenes; Humans; Male; Middle Aged; Oscillometry; Physical Exertion; Piperazines; Placebos; Plethysmography; Regional Blood Flow; Vasodilator Agents | 1974 |
6 other study(ies) available for fluorobenzenes and Arteriosclerosis
| Article | Year |
|---|---|
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Topics: Adult; Arteriosclerosis; C-Reactive Protein; Carotid Intima-Media Thickness; Cerebral Infarction; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Triglycerides | 2014 |
Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Cell Adhesion; Cholesterol; Cytokines; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Macrophages; Mice; Mice, Transgenic; Monocytes; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability.
Topics: Arteriosclerosis; Base Sequence; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Fluorobenzenes; Humans; Macrophages; Matrix Metalloproteinase 7; Molecular Sequence Data; Monocytes; Polymerase Chain Reaction; Pyrimidines; Reference Values; RNA, Messenger; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides | 2004 |
Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Benzimidazoles; Biphenyl Compounds; CD40 Antigens; Cholesterol; Drug Synergism; Drug Therapy, Combination; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrimidines; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2004 |
Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo.
Topics: Animals; Antibodies, Monoclonal; Arteriosclerosis; Borohydrides; Cell Adhesion; Chromatography, High Pressure Liquid; Endothelium, Vascular; Fluorobenzenes; Hydroxylamines; Lipoproteins, LDL; Mass Spectrometry; Mice; Monocytes; Oxidation-Reduction; Phospholipid Ethers; Phospholipids; Rabbits | 1997 |
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |